A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Postmenopausal females (ages 40-74) with predominantly urge urinary incontinence overactive bladder episodes.

• Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards.

Exclusion Criteria:

• Patients must not suffer from diabetes insipidus

• Hyperglycemia

• Hypercalcemia

• Orthostatic hypotension

• Active/recurrent urinary tract infections (>6 episodes per year)

• Patients must be willing to discontinue their current OAB medication therapy.